Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aravive stock

Learn how to easily invest in Aravive stock.

Aravive Inc is a biotechnology business based in the US. Aravive shares (ARAV) are listed on the NASDAQ and all prices are listed in US Dollars. Aravive employs 23 staff and has a trailing 12-month revenue of around $6.1 million.

How to buy shares in Aravive

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ARAV – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Aravive stock price (NASDAQ: ARAV)

Use our graph to track the performance of ARAV stocks over time.

Aravive shares at a glance

Information last updated 2022-10-02.
Latest market close$0.79
52-week range$0.58 - $4.25
50-day moving average $0.84
200-day moving average $1.50
Wall St. target price$18.20
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-2.12

Buy Aravive shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aravive stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aravive price performance over time

Historical closes compared with the close of $0.794 from 2022-10-05

1 week (2022-09-29) -10.27%
1 month (2022-09-06) 16.52%
3 months (2022-07-06) -12.74%
6 months (2022-04-05) -58.21%
1 year (2021-10-06) -77.88%
2 years (2020-10-06) -83.73%
3 years (2019-10-04) 7.08
5 years (2017-10-06) 2.65

Aravive financials

Revenue TTM $6.1 million
Gross profit TTM $-30,099,000
Return on assets TTM -52.84%
Return on equity TTM -118.09%
Profit margin 0%
Book value $0.99
Market capitalisation $24.9 million

TTM: trailing 12 months

Aravive share dividends

We're not expecting Aravive to pay a dividend over the next 12 months.

Have Aravive's shares ever split?

Aravive's shares were split on a 1:6 basis on 16 October 2018. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aravive shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Aravive shares which in turn could have impacted Aravive's share price.

Aravive share price volatility

Over the last 12 months, Aravive's shares have ranged in value from as little as $0.58 up to $4.25. A popular way to gauge a stock's volatility is its "beta".

ARAV.US volatility(beta: 2.42)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aravive's is 2.4219. This would suggest that Aravive's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aravive overview

Aravive, Inc. , a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a strategic collaboration agreement with WuXi Biologics (Hong Kong) Limited to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc.

Frequently asked questions

What percentage of Aravive is owned by insiders or institutions?
Currently 41.513% of Aravive shares are held by insiders and 18.36% by institutions.
How many people work for Aravive?
Latest data suggests 23 work at Aravive.
When does the fiscal year end for Aravive?
Aravive's fiscal year ends in December.
Where is Aravive based?
Aravive's address is: River Oaks Tower, Houston, TX, United States, 77098
What is Aravive's ISIN number?
Aravive's international securities identification number is: US03890D1081
What is Aravive's CUSIP number?
Aravive's Committee on Uniform Securities Identification Procedures number is: 03890D108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site